Insmed CEO trades 10,699 shares under 10b5-1 plan
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Insmed Inc Chair and CEO William Lewis reported option exercises and share sales in Insmed common stock. On April 6, 2026, he exercised stock options for a total of 10,699 shares at strike prices of $30.46 and $17.16 per share, then sold 10,699 shares in open-market transactions at weighted average prices around $161.73, $163.23, and $164.01. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, he directly owned about 301,185 shares of common stock, with an additional 233,924 shares held indirectly through the Katie Procter Dynasty Trust.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,699 shares ($1.48M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Lewis William
Role
Chair and CEO
Sold
10,699 shs ($1.75M)
Approx. gross sale proceeds
$1.75M
Approx. exercise cost
$267K
Approx. pre-tax spread
$1.48M
Share of Position Sold
3.4%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,259 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 4,440 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,259 | $30.46 | $191K |
| Exercise | Common Stock | 4,440 | $17.16 | $76K |
| Sale | Common Stock | 787 | $161.73 | $127K |
| Sale | Common Stock | 8,478 | $163.23 | $1.38M |
| Sale | Common Stock | 1,434 | $164.01 | $235K |
| Holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 74,894 contracts (Direct);
Common Stock — 301,185 shares (Direct);
Common Stock — 233,924 shares (Indirect, By the Katie Procter Dynasty Trust)
Holdings Before and After:
Stock Option (right to buy), 85,593 to 74,894 contracts (Direct);
Common Stock, 301,185 to 301,185 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 787 shares sold at prices ranging from $161.65 to $162.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 8,478 shares sold at prices ranging from $162.66 to $163.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. This is the weighted average sales price representing 1,434 shares sold at prices ranging from $163.66 to $164.36 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F5. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Key Figures
Shares sold: 10,699 shares
Sale price (block 1): $161.73 per share
Sale price (block 2): $163.23 per share
+5 more
8 metrics
Shares sold
10,699 shares
Open-market sales of common stock on April 6, 2026
Sale price (block 1)
$161.73 per share
Weighted average price for 787 shares sold
Sale price (block 2)
$163.23 per share
Weighted average price for 8,478 shares sold
Sale price (block 3)
$164.01 per share
Weighted average price for 1,434 shares sold
Options exercised (strike $30.46)
6,259 shares
Stock option exercise into common stock
Options exercised (strike $17.16)
4,440 shares
Stock option exercise into common stock
Direct holdings after trades
301,185 shares
Common stock directly owned after April 6, 2026 transactions
Indirect trust holdings
233,924 shares
Held by the Katie Procter Dynasty Trust
Key Terms
Rule 10b5-1 trading plan, Stock Option (right to buy), weighted average sales price, open-market sale, +2 more
6 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
weighted average sales price financial
"This is the weighted average sales price representing 8,478 shares sold at prices..."
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
vesting schedule financial
"The options became exercisable based on the following vesting schedule: 25% vested..."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did INSM CEO William Lewis report on April 6, 2026?
William Lewis reported exercising options for 10,699 Insmed shares and selling 10,699 common shares in open-market trades on April 6, 2026. The filing shows both the option exercises and subsequent sales as part of his equity activity that day.
What stock options did the INSM CEO exercise in this Form 4 filing?
The CEO exercised stock options to acquire 6,259 Insmed shares at a $30.46 strike price and 4,440 shares at a $17.16 strike price. These option grants vested over time under a schedule described in the filing’s vesting footnote.
Were the INSM CEO’s stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. Such pre-arranged plans schedule trades in advance to help separate them from short-term market timing decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
